Cyclacel pharmaceuticals highlights publication of preclinical data showing that plogosertib is active in a hard-to-treat subtype of liver cancer

- fibrolamellar hepatocellular carcinoma (flc) has no approved treatment and occurs mostly in adolescents and young adults -

CYCC Ratings Summary

CYCC Quant Ranking